Home » Stocks » Allergan

Allergan plc (AGN)

May 8, 2020 - AGN was delisted after being acquired by ABBV
Stock Price: $193.02 USD 0.00 (0.00%)
Updated May 8, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 63.36B
Revenue (ttm) 16.10B
Net Income (ttm) -2.49B
Shares Out 328.28M
EPS (ttm) -7.57
PE Ratio n/a
Forward PE 11.89
Dividend $2.96
Dividend Yield 1.53%

Stock Quote

Trading Day May 8, 2020
Last Price $193.02
Previous Close $193.02
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 191.64 - 193.38
Day's Volume 0
52-Week Range 114.27 - 202.22

More Stats

Market Cap 63.36B
Enterprise Value 80.85B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 328.28M
Float 327.79M
EPS (basic) -7.60
EPS (diluted) -7.57
FCF / Share 17.50
Dividend $2.96
Dividend Yield 1.53%
Earnings Yield n/a
FCF Yield 9.09%
Payout Ratio n/a
Shares Short 15.01M
Short Ratio 3.22
Short % of Float 4.58%
Beta 1.20
PE Ratio n/a
Forward PE 11.89
P/FCF Ratio 11.00
PS Ratio 3.94
PB Ratio 1.10
Revenue 16.10B
Operating Income -3.44B
Net Income -2.49B
Free Cash Flow 5.76B
Net Cash -17.49B
Net Cash / Share -53.28
Gross Margin 84.83%
Operating Margin -21.34%
Profit Margin -15.40%
FCF Margin 35.78%
ROA 0.74%
ROE -4.15%
ROIC -13.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (14)

Buy 2
Overweight 0
Hold 12
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$189.00*
(-2.08% downside)
Low
188
Current: $193.02
High
190
Target: 189.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue16,08915,78715,94114,57112,6884,6772,6035,9154,5843,567
Revenue Growth1.91%-0.96%9.4%14.84%171.32%79.69%-56%29.02%28.53%-
Gross Profit13,59613,59613,77312,7109,9362,9729582,5212,0181,568
Operating Income-4,445-6,248-5,921-1,826-3,131-2,567-369316523305
Net Income-5,271-5,096-4,12614,9733,915-1,631-75097.30261184
Shares Outstanding329337334385368220142126125122
Earnings Per Share-16.02-15.26-13.1938.1810.01-7.42-5.270.762.061.48
EPS Growth---281.42%----63.11%39.19%-
Dividend Per Share2.962.882.80-0.100.200.10---
Dividend Growth2.78%2.86%---50%100%----
Operating Cash Flow7,2395,6406,0791,4464,6062,2431,214666632571
Capital Expenditures-352-223-343-298-315-225-171-130-120-53.90
Free Cash Flow6,8875,4175,7361,1484,2912,0181,043536512517
Cash & Equivalents5,9151,9076,44913,2261,105251332328224294
Total Debt23,22023,79830,07532,76942,53015,5319,0526,4331,0331,016
Net Cash / Debt-17,305-21,890-23,626-19,543-41,425-15,280-8,721-6,105-809-722
Assets94,699101,788118,342128,986135,58352,75822,72614,1156,6985,687
Liabilities36,50336,65744,50552,78658,99424,42313,18910,2583,1362,404
Book Value58,17465,11473,82176,19376,59128,3319,5323,8343,5643,282
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allergan plc
Country Ireland
Employees 17,400

Stock Information

Ticker Symbol AGN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: AGN
IPO Date February 17, 1993

Description

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.